Anti-Suicide Drugs Market Analysis and Forecasted Healthcare Industry With Key Companies Pfizer, AstraZeneca, Eli Lilly and Company, Allergan, GlaxoSmithKline, Merck

Depression is one of the major healthcare burdens worldwide leading to lower productivity and in severe cases leading to suicidal tendencies. Anti-depressant and anti-psychotic drugs are especially high in demand during economic crisis and social negligence. These drugs also serve as a therapy for preventing suicidal thoughts and attempts. However, overdose of these drugs can be fatal and therefore, needs to be administered under the direction of a physician. Extensive research related to suicide treatment is expected to provide a better solution to the global population during the latter half of the forecast period (2016-2024). This would improve the outlook of global anti-suicide drugs market and would help in reducing deaths due to suicide.

The global anti-suicide drugs market was valued at US$ 3,318.3 million in 2015 and is expected to witness a moderate CAGR of 4.2% during the forecast period (2016 – 2024).

Major players operating in the global anti-suicide drugs market include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson. High healthcare expenditure in developed economies of North America and Europe is responsible for a higher market size of anti-suicidal drugs in these regions. Moreover, developed regions offer better healthcare infrastructure and are usually early adopters of new therapies. The anti-suicide drugs market in North America and Europe is expected to gain significant traction during the latter half of the forecast period, with the launch of anti-suicidal drug. Increasing healthcare expenditure in emerging economies and high prevalence of suicides in these regions is expected to bring about a paradigm shift in the market. Companies are expected to focus on capitalizing on lucrative opportunities in these regions at the turn of the following decade. This would ensure sustained growth for the market in the foreseeable future.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/10

This report provides in-depth analysis of the anti-suicide drugs and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global anti-suicide drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson

Insights from this report would allow marketers and the management of companies to make informed decision with respect to their future product launch, competitive scenario, geographic expansion, and marketing tactics

The global anti-suicide devices market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts

Various strategy matrices used in analyzing the anti-suicide drugs market would provide stakeholders vital inputs to make strategic decisions accordingly

According to the World Health Organization (WHO), suicide accounted for 1.4% of the total deaths worldwide in 2012, accounting for around 800 thousand deaths each year. Russia, India, Republic of Korea, Guyana, Lithuania, Sri Lanka, Hungary, Kazakhstan, and Japan are among the nations with high suicidal rates as per the WHO 2012 data. Emerging nations therefore possess immense opportunity for anti-suicidal drugs. However, being the first ever oral anti-suicidal therapeutic drug, companies are likely to capture the anti-suicide drugs market in developed regions such as North America and Western Europe. This mainly due to rapid adoption of new therapies and accessibility to healthcare facilities in these regions as compared to emerging economies.

Request A Sample Copy Of This Report:
https://www.coherentmarketinsights.com/insight/request-sample/10

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.